InMed Pharmaceuticals
11 hedge funds and large institutions have $109K invested in InMed Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.47% less ownership
Funds ownership: 0.62% → 0.15% (-0.47%)
53% less capital invested
Capital invested by funds: $234K → $109K (-$125K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$125K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.4K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$2.94K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.88K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$32 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$196K |
| 2 |
VF
Virtu Financial
New York
|
-$36K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$65 |
| 4 |
Morgan Stanley
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $84K | +$125K | +3,875 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $20.3K | +$30.4K | +941 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $2.83K | +$2.88K | +89 | +212% |
|
|
4
Bank of America
Charlotte,
North Carolina
| $1.97K | +$2.94K | +91 | New |
|
|
TWC
5
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $125 | – | – | – |
|
6
BlackRock
New York
| $54 | – | – | – |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $43 | -$65 | -2 | -50% |
|
|
AWM
8
AllSquare Wealth Management
Albany,
New York
| $23 | – | – | – |
|
|
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $21 | – | – | – |
|
|
10
National Bank of Canada
Montreal,
Quebec, Canada
| $13 | +$32 | +1 | New |
|
|
ASN
11
Advisory Services Network
Atlanta,
Georgia
| $6 | – | – | – |
|
|
TWA
12
TCI Wealth Advisors
Tucson,
Arizona
| $6 | – | – | – |
|
|
GCM
13
Gables Capital Management
Miami,
Florida
| $1 | – | – | – |
|
|
AC
14
Armistice Capital
New York
| – | -$196K | -4,858 | Closed |
|
|
VF
15
Virtu Financial
New York
| – | -$36K | -886 | Closed |
|
|
16
Morgan Stanley
New York
| – | -$2 | – | – |
|
INM Hedge Fund Activity: Q1 2023 in Review
11 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q1 2023, worth a combined $109K — down 53% from $234K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new INM positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $125K. The largest seller was Armistice Capital, exiting entirely with an estimated $196K sold.
- 11 institutional investors held InMed Pharmaceuticals (INM) as of Q1 2023, up from 9 in Q4 2022.
- Funds reported $109K of InMed Pharmaceuticals stock for Q1 2023, down 53% quarter-over-quarter.
- 4 funds opened new InMed Pharmaceuticals positions in Q1 2023 and 2 closed out, a net change of +2 holders.
- The largest InMed Pharmaceuticals buyer in Q1 2023 was Renaissance Technologies, an estimated $125K added.
- The largest InMed Pharmaceuticals seller in Q1 2023 was Armistice Capital, an estimated $196K sold.
Based on aggregated 13F filings for Q1 2023.